AKEBIA THERAPEUTICS, INC. Stock-Based Compensation
AKEBIA THERAPEUTICS, INC. (AKBA) reported Stock-Based Compensation of $6.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.23M, a 20.55% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.67M, a 67.72% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.20M, a 88.51% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.22M, a 95.69% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $11.28M, a 45.12% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $7.78M, a 16.55% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $9.32M, a 47.80% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $17.85M, a 21.49% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.89M 10-Q · filed 2026-08-05 | $10.09M derived: sum of 3 quarters · filed 2026-08-05 | $13.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.67M 10-Q · filed 2026-05-07 | $6.87M derived: sum of 2 quarters · filed 2026-05-07 | $10.09M derived: sum of 3 quarters · filed 2026-05-07 | $12.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.42M derived: sum of 2 quarters · filed 2026-02-26 | $9.10M derived: sum of 3 quarters · filed 2026-08-05 | $11.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.90M derived: sum of 2 quarters · filed 2026-08-05 | $8.08M 10-Q · filed 2025-11-10 | $9.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.86M 10-Q · filed 2026-08-05 | $6.56M derived: sum of 3 quarters · filed 2026-08-05 | $8.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.19M 10-Q · filed 2026-05-07 | $3.88M derived: sum of 2 quarters · filed 2026-05-07 | $5.53M derived: sum of 3 quarters · filed 2026-05-07 | $7.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.34M derived: sum of 2 quarters · filed 2026-02-26 | $5.42M derived: sum of 3 quarters · filed 2026-02-26 | $7.78M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.72M derived: sum of 2 quarters · filed 2025-11-10 | $6.08M 10-Q · filed 2025-11-10 | $7.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.43M 10-Q · filed 2025-08-07 | $5.95M derived: sum of 3 quarters · filed 2026-02-26 | $7.77M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.36M 10-Q · filed 2025-05-08 | $3.87M derived: sum of 2 quarters · filed 2026-02-26 | $5.70M derived: sum of 3 quarters · filed 2026-02-26 | $9.19M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.34M derived: sum of 2 quarters · filed 2026-02-26 | $6.83M derived: sum of 3 quarters · filed 2026-02-26 | $9.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.31M derived: sum of 2 quarters · filed 2024-11-07 | $7.80M 10-Q · filed 2024-11-07 | $10.84M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.98M 10-Q · filed 2024-08-08 | $9.02M derived: sum of 3 quarters · filed 2024-08-08 | $12.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.49M 10-Q · filed 2024-05-09 | $5.53M derived: sum of 2 quarters · filed 2024-05-09 | $8.88M derived: sum of 3 quarters · filed 2024-05-09 | $15.80M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.40M derived: sum of 2 quarters · filed 2024-03-14 | $13.31M derived: sum of 3 quarters · filed 2024-03-14 | $17.85M 10-K · filed 2024-03-14 |
| 2022-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $10.27M derived: sum of 2 quarters · filed 2023-11-08 | $14.81M 10-Q · filed 2023-11-08 | $19.44M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $6.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $11.45M 10-Q · filed 2023-08-28 | $16.09M derived: sum of 3 quarters · filed 2023-08-28 | $21.68M derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | $4.54M 10-Q · filed 2023-05-08 | $9.17M derived: sum of 2 quarters · filed 2023-08-28 | $14.77M derived: sum of 3 quarters · filed 2023-08-28 | $21.28M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | $4.64M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $10.23M derived: sum of 2 quarters · filed 2023-08-28 | $16.74M derived: sum of 3 quarters · filed 2023-08-28 | $22.73M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $12.11M derived: sum of 2 quarters · filed 2022-11-03 | $18.10M 10-Q · filed 2022-11-03 | $24.19M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-06-30 | $6.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $12.51M 10-Q · filed 2022-08-04 | $18.59M derived: sum of 3 quarters · filed 2023-08-28 | $25.19M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-03-31 | $5.99M 10-Q · filed 2022-05-09 | $12.08M derived: sum of 2 quarters · filed 2023-08-28 | $18.67M derived: sum of 3 quarters · filed 2023-08-28 | $25.54M derived: sum of 4 quarters · filed 2023-08-28 |
| 2020-12-31 | $6.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $12.68M derived: sum of 2 quarters · filed 2023-08-28 | $19.54M derived: sum of 3 quarters · filed 2023-08-28 | $24.46M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | $6.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $13.46M derived: sum of 2 quarters · filed 2021-11-04 | $18.37M 10-Q · filed 2021-11-04 | $23.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $6.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.78M 10-Q · filed 2021-08-05 | $16.71M derived: sum of 3 quarters · filed 2022-03-01 | $19.33M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $4.92M 10-Q · filed 2021-05-10 | $9.85M derived: sum of 2 quarters · filed 2022-03-01 | $12.46M derived: sum of 3 quarters · filed 2022-03-01 | $14.75M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.55M derived: sum of 2 quarters · filed 2022-03-01 | $9.83M derived: sum of 3 quarters · filed 2022-03-01 | $11.93M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.90M derived: sum of 2 quarters · filed 2020-11-05 | $6.99M 10-Q · filed 2020-11-05 | $19.05M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $4.38M 10-Q · filed 2020-08-10 | $16.44M derived: sum of 3 quarters · filed 2021-02-25 | $18.69M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.09M 10-Q · filed 2020-05-05 | $14.16M derived: sum of 2 quarters · filed 2021-02-25 | $16.41M derived: sum of 3 quarters · filed 2021-02-25 | $18.90M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $12.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $14.31M derived: sum of 2 quarters · filed 2021-02-25 | $16.81M derived: sum of 3 quarters · filed 2021-02-25 | $19.04M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.75M derived: sum of 2 quarters · filed 2019-11-12 | $6.98M 10-Q · filed 2019-11-12 | $9.17M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $4.72M 10-Q · filed 2019-08-08 | $6.92M derived: sum of 3 quarters · filed 2020-03-12 | $9.07M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $2.23M 10-Q · filed 2019-05-09 | $4.42M derived: sum of 2 quarters · filed 2020-03-12 | $6.58M derived: sum of 3 quarters · filed 2020-03-12 | $9.08M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.34M derived: sum of 2 quarters · filed 2020-03-12 | $6.85M derived: sum of 3 quarters · filed 2020-03-12 | $8.87M 10-K · filed 2020-03-12 |
| 2017-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $4.66M derived: sum of 2 quarters · filed 2018-11-08 | $6.67M 10-Q · filed 2018-11-08 | $8.40M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $4.52M 10-Q · filed 2018-08-08 | $6.25M derived: sum of 3 quarters · filed 2019-03-26 | $7.87M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | $2.02M 10-Q · filed 2018-05-09 | $3.74M derived: sum of 2 quarters · filed 2019-03-26 | $5.37M derived: sum of 3 quarters · filed 2019-03-26 | $6.59M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $3.35M derived: sum of 2 quarters · filed 2019-03-26 | $4.57M derived: sum of 3 quarters · filed 2019-03-26 | $5.83M 10-K · filed 2019-03-26 |
| 2016-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.85M derived: sum of 2 quarters · filed 2016-11-09 | $4.10M 10-Q · filed 2016-11-09 | $5.43M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $2.47M 10-Q · filed 2016-08-08 | $3.80M derived: sum of 3 quarters · filed 2018-03-12 | $4.96M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $1.25M 10-Q · filed 2016-05-05 | $2.58M derived: sum of 2 quarters · filed 2018-03-12 | $3.74M derived: sum of 3 quarters · filed 2018-03-12 | $4.84M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $2.49M derived: sum of 2 quarters · filed 2018-03-12 | $3.59M derived: sum of 3 quarters · filed 2018-03-12 | $4.71M 10-K · filed 2018-03-12 |
| 2015-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.26M derived: sum of 2 quarters · filed 2016-11-09 | $3.39M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $2.22M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $1.13M 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $6.01M 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |